EGFR and non-small cell lung carcinoma: The discovery of EGFR activating mutations, 90% of which occur as an exon 19 deletion (19del) or exon 21 point mutation (L858R), as a predictor of patient response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) represented a milestone and paradigm shift in the treatment of NSCLC.